Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13798 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Heejae Won und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Drug Interactions, Cross-Over Studies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Fexuprazan, a novel potassium‐competitive acid blocker, is expected to be used for the prevention of nonsteroidal anti‐inflammatory drugs (NSAIDs) induced ulcer. This study aimed to evaluate pharmacokinetic (PK) interactions between fexuprazan and NSAIDs in healthy subjects. A randomized, open‐label, multicenter, six‐sequence, one‐way crossover study was conducted in healthy male subjects. Subjects randomly received one of the study drugs (fexuprazan 40 mg BID, celecoxib 200 mg BID, naproxen 500 mg BID, or meloxicam 15 mg QD) for 5 or 7 days in the first period followed by the combination of fexuprazan and one of NSAIDs for the same days and the perpetrator additionally administered for 1–2 days in the second period. Serial blood samples for PK analysis were collected until 48‐ or 72‐h post‐dose at steady state. PK parameters including maximum plasma concentration at steady state ( C max,ss ) and area under plasma concentration–time curve over dosing interval at steady state (AUC τ,ss ) were compared between monotherapy and combination therapy. The PKs of NSAIDs were not significantly altered by fexuprazan. For fexuprazan, differences in PK parameters (22% in C max , 19% in AUC τ,ss ) were observed when co‐administered with naproxen, but not clinically significant. The geometric mean ratio (90% confidence interval) of combination therapy to monotherapy for C max,ss and AUC τ,ss was 1.22 (1.02–1.46) and 1.19 (1.00–1.43), respectively. There were no significant changes in the systemic exposure of fexuprazan by celecoxib and meloxicam. Fexuprazan and NSAIDs did not show clinically meaningful PK interactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea.
- Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
- Daewoong Pharmaceutical Co., Ltd., Seoul, Korea.
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Korea.
- Department of Pharmacology, School of Medicine, Jeonbuk National University, Jeonju, Korea.
ORCID-Profile: Heejae Won, Eunwoo Kim, Joo-Youn Cho, In-Jin Jang, Jae-Yong Chung, Min-Gul Kim, SeungHwan Lee
Zitieren
APA
Won, H., Kim, E., Chae, J., Lee, H., Cho, J. Y., Jang, I. J., Chung, J. Y., Kim, M. G., & Lee, S. (2024). Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males. Clinical and Translational Science. https://doi.org/10.1111/cts.13798
Vancouver
Won H, Kim E, Chae J, Lee H, Cho JY, Jang IJ, et al. Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males. Clinical and Translational Science. 2024. doi:10.1111/cts.13798
BibTeX
@article{Won2024,
author = {Won, Heejae and Kim, Eunwoo and Chae, Jihye and Lee, Hyejung and Cho, Joo-Youn and Jang, In-Jin and Chung, Jae-Yong and Kim, Min-Gul and Lee, SeungHwan},
title = {Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13798}
}
EUVIMED